Physician profile
David Niedermeier
NPI 1760683379
$1,466.82
in general payments reported to CMS, 2019-2025
25 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $65.76 · 2021: $167 · 2022: $90.76 · 2023: $323 · 2024: $426 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $311.78 | 2021-2025 | |
| Pfizer INC. | $241.68 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $118.93 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $118.20 | 2024-2025 | Rybelsus, Ozempic |
| Amgen INC. | $92.40 | 2022-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $76.70 | 2019-2025 | Gardasil 9, Capvaxive, Rotateq |
| E.R. Squibb & Sons, L.L.C. | $60.78 | 2019-2020 | |
| Astellas Pharma US INC | $52.04 | 2019-2023 | Veozah |
| Corium, LLC | $41.55 | 2023 | Azstarys |
| Lilly USA, LLC | $37.49 | 2020-2023 | Mounjaro |
| Exact Sciences Corporation | $36.72 | 2023-2024 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $28.48 | 2025 | Fanapt |
| Tempus Ai, INC | $24.49 | 2024 | |
| Dexcom, INC. | $24.19 | 2024 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $22.80 | 2023 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.55 | 2020 | |
| Alfasigma USA, INC. | $22.18 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $20.25 | 2024 | Bd Onclarity |
| Si-Bone, INC. | $19.38 | 2019 | |
| Sanofi Pasteur INC. | $19.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.48 | 2021 | |
| Allergan, INC. | $16.21 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.59 | 2019 | |
| Eisai INC. | $13.56 | 2021 | |
| Glaxosmithkline, LLC. | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Niedermeier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.